The data show that Regorafenib is equivalent to TAS-102 in metastatic CRC.

Published Date: 08 Mar 2023

A real-world comparison showed similar overall survival in patients with refractory metastatic CRC treated with regorafenib or trifluridine/tipiracil (TAS-102).

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Researchers find distinct cell receptors with the potential for new treatments.

2.

Breast cancer patients' arms swell less after an effective lymph node transfer.

3.

Telehealth in the pandemic era resulted in fewer therapy interruptions.

4.

Too Many Chest CTs for Incidental Lung Nodules?

5.

Global warming could be driving up women's cancer risk, find researchers


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot